This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.
Full Title of Study: “Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: November 2011
Bulimia nervosa (BN) is a serious eating disorder that is characterized by frequent uncontrolled eating binges. These binges are often followed by compensatory behavior, including the following: self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications to induce purging; fasting; or excessive exercise. If left untreated, BN can lead to many serious health issues: tooth decay; irregular menstruation; bowel damage; constipation; heart and kidney disease; intestinal damage; puffiness, especially in the face and fingers; increased hair growth on the face and body; and mineral imbalances in the body. Although there is significant existing knowledge about the characteristics and treatment of BN, more information is needed about gastrointestinal (GI) function and its effect on binge eating behavior. This study will determine the effectiveness of the antibiotic erythromycin in enhancing GI function and decreasing the frequency of binge eating in people with BN.
Participants in this 8-week, double-blind study will first undergo gastric emptying and GI hormone release testing for 1 day. Within 1 week of completing these pre-treatment tests, participants will be randomly assigned to receive either erythromycin or placebo for 6 weeks. Upon medication assignment, participants will meet with a psychiatrist to receive their assigned medication. Participants will receive medication at weekly study visits. Medication dosage will be increased if symptoms do not improve, or decreased if adverse medication side effects are reported. A final day of gastric emptying and GI hormone release testing, as well as routine blood tests, will take place in Week 7, after 6 weeks of medication treatment. Participants' weight will be measured at Weeks 1, 4, and 7. Participants will also receive an EKG 1 week after each upward dosage adjustment. Patients will be informed of their medication assignment at the Week 7 study visit, and will be referred to a non-study clinician for further treatment.
For information on related studies, please see NCT00308776 and NCT00307190.
- Drug: Erythromycin
- Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
- Drug: Placebo
- Placebo, 250 mg or 500 mg, three times a day for 6 weeks
Arms, Groups and Cohorts
- Experimental: Erythromycin
- Subjects with Bulimia Nervosa will take erythromycin.
- Placebo Comparator: Placebo
- Participants will take matched placebo.
Clinical Trial Outcome Measures
- Binge Frequency
- Time Frame: Measured at Week 7
- Binge frequency was assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit.
- Percent of Meal Remaining/Minute
- Time Frame: Measured at Week 7
- percent of meal remaining/minute
Participating in This Clinical Trial
- Meets criteria for bulimia nervosa
- Duration of illness is greater than 1 year
- Self-induces vomiting
- Weighs 80%-120 % of ideal weight
- Significant medical illness
- Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by American Psychiatric Association criteria
- Moderate to severe depression, as defined by a score greater than 18 on the Hamilton Depression Scales
- Current diagnosis of organic mental disorder, factitious disorder, or malingering
- History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with assessment or compliance with the study procedures
- At risk for suicide
- Current psychotropic medications and current medications that affect GI function or that inhibit or induce cytochrome three A gene expression
- Currently pregnant, lactating, or planning to become pregnant
- Drug or alcohol abuse within the 3 months prior to study entry
- Abnormal EKG at baseline or 1 week following each upward dosage adjustment
- Known intolerance to erythromycin, or related antibiotics
- Abnormal results on liver function tests
- Electrolyte abnormalities
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 55 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
- Provider of Information About this Clinical Study
- Principal Investigator: B. Timothy Walsh, Research Scientist – New York State Psychiatric Institute
- Overall Official(s)
- B. T. Walsh, MD, Principal Investigator, New York State Psychiatric Institute at Columbia University Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.